YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Good mental health concept] * The Trump administration is rolling back $2B in cuts to mental health and addiction programs, _NPR _reported, citing a Trump administration official. * Letters restoring the funding are expected to be sent in…
Sagimet Biosciences Inc. SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to t…
CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, an…
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045…
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, to…
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reporte…
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respiratory compromise rates VOLITION data to…
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using cont…
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant Evidence of CNS Activity of TRV045 on Day 4 as Me…
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing wi…
Trevena, Inc. CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS…
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, t…
Trevena, Inc. OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n…
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids (n=982) New resp…
Trevena, Inc. $3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China CHESTERBR…
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commercial sale in China CHESTERBROOK, Pa., May…
CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, tod…
Trevena, Inc. CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS)…
Participants Barry Shin; Senior VP & CFO; Trevena, Inc. Carrie L. Bourdow; President, CEO & Director; Trevena, Inc. Mark A. Demitrack; Senior VP & Chief Medical Officer; Trevena, Inc. Patricia M. Drake; Senior VP & Chief Commercial Officer…
Trevena, Inc. OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilutive tranche from R-Bri…
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilutive tranche from R-Bridge upon first…
Aspira (AWH) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly…
Trevena, Inc. Company to host a Conference Call & Webcast at 8:00 a.m. ET CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of nov…
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, tod…
Trevena, Inc. Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on…
Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on first commerc…
Trevena, Inc. CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS)…
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, tod…
Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript March 31, 2023 Operator: Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. I would now like…
Trevena, Inc. OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMIS…
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMIS patients at W…
Trevena, Inc. Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues to advance as…
Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues to advance as a potential tr…
Trevena, Inc. Company to host a Conference Call & Webcast at 8:00 a.m. ET CHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of n…
CHESTERBROOK, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, t…
Shares of Trevena TRVN gained 2.19% on Mar 8, after the company announced the initiation of a new study that complements the ongoing phase I proof-of-concept study to evaluate TRV045 — a novel sphingosine-1- phosphate receptor modulator se…